

Date: 03 February 2025

To

The Head, Listing Compliance Department <b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001 <b>Scrip Code: 544293</b>	The Head, Listing Compliance Department <b>The National Stock Exchange of India Limited</b> Exchange Plaza, Plot No. C/1. G Block Bandra -Kurla Complex, Bandra (East) Mumbai- 400 051 <b>Scrip Symbol : SURAKSHA</b>
---	--

Dear Sir / Ma'am,

**Reg: Intimation under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Sub: Notice of the Board Meeting**

Pursuant to Regulation 29(1)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on **Saturday, 08 February 2025**, at the registered office of the Company, inter-alia, to consider, approve and take on record the unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended 31 December 2024.

Further, in continuation to our intimation letter dated **Thursday, 26 December 2024**, regarding closure of trading window for the aforesaid purpose, and in accordance with the Company's Internal Code of Conduct for Prohibition of Insider Trading, framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the securities of the Company is already closed from 01 January 2025 and shall continue to remain close for directors, KMP's, designated persons, employees, connected persons and their immediate relatives until the expiry of 48 hours after the announcement of the unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended 31 December 2024 to the Stock Exchanges.

This may please be taken on record.

**For Suraksha Diagnostic Limited**

---

**Mamta Jain**  
**Company Secretary and Compliance Officer**  
**Membership No.: ACS 25654**